S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
NASDAQ:DYAI

Dyadic International (DYAI) Stock Price, News & Analysis

$1.59
0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
$1.50
$1.62
50-Day Range
$1.29
$1.87
52-Week Range
$1.19
$2.40
Volume
14,344 shs
Average Volume
21,571 shs
Market Capitalization
$46.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Dyadic International MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
277.4% Upside
$6.00 Price Target
Short Interest
Healthy
0.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.44) to ($0.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.22 out of 5 stars

Medical Sector

748th out of 911 stocks

Biological Products, Except Diagnostic Industry

129th out of 152 stocks

DYAI stock logo

About Dyadic International Stock (NASDAQ:DYAI)

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

DYAI Stock Price History

DYAI Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Q4 2023 Dyadic International Inc Earnings Call
Recap: Dyadic International Q4 Earnings
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Dyadic to Attend Industry Events in April
Dyadic to Attend Industry Events in March
DYAI Aug 2024 2.500 call
DYAI Apr 2024 2.500 call
DYAI: Catching Up With Dyadic
See More Headlines
Receive DYAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/20/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:DYAI
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+277.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-6,800,000.00
Net Margins
-234.39%
Pretax Margin
-234.39%

Debt

Sales & Book Value

Annual Sales
$2.90 million
Book Value
$0.20 per share

Miscellaneous

Free Float
21,064,000
Market Cap
$46.07 million
Optionable
Optionable
Beta
0.60
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

DYAI Stock Analysis - Frequently Asked Questions

Should I buy or sell Dyadic International stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DYAI shares.
View DYAI analyst ratings
or view top-rated stocks.

What is Dyadic International's stock price target for 2024?

1 brokerages have issued 12-month target prices for Dyadic International's stock. Their DYAI share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 277.4% from the stock's current price.
View analysts price targets for DYAI
or view top-rated stocks among Wall Street analysts.

How have DYAI shares performed in 2024?

Dyadic International's stock was trading at $1.61 on January 1st, 2024. Since then, DYAI shares have decreased by 1.2% and is now trading at $1.59.
View the best growth stocks for 2024 here
.

When is Dyadic International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our DYAI earnings forecast
.

How were Dyadic International's earnings last quarter?

Dyadic International, Inc. (NASDAQ:DYAI) posted its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. The biotechnology company earned $0.69 million during the quarter, compared to analyst estimates of $0.61 million. Dyadic International had a negative trailing twelve-month return on equity of 81.57% and a negative net margin of 234.39%. During the same period last year, the company earned ($0.09) EPS.

What other stocks do shareholders of Dyadic International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyadic International investors own include Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL), Pfizer (PFE), Advanced Micro Devices (AMD), Endeavour Silver (EDR), Mandalay Resources (MND), Alibaba Group (BABA) and Chimerix (CMRX).

How do I buy shares of Dyadic International?

Shares of DYAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DYAI) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners